Cargando…

Assessment of Food and Drug Administration– and European Medicines Agency–Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

IMPORTANCE: For patients with cancer treated with palliative intent, quality of life (QOL) is a critical aspect of treatment decision-making, alongside survival. However, regulatory approval can be based solely on survival measures or antitumor activities, without QOL evidence. OBJECTIVE: To investi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arciero, Vanessa, Delos Santos, Seanthel, Koshy, Liza, Rahmadian, Amanda, Saluja, Ronak, Everest, Louis, Parmar, Ambica, Chan, Kelvin K. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879236/ https://www.ncbi.nlm.nih.gov/pubmed/33570573 http://dx.doi.org/10.1001/jamanetworkopen.2020.33004

Ejemplares similares

Examining the association between oncology drug clinical benefit and the time to public reimbursement
por: Thomson, Sasha, et al.
Publicado: (2021)

Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs
por: Saluja, Ronak, et al.
Publicado: (2021)

Value‐based pricing: Toward achieving a balance between individual and population gains in health benefits
por: Parmar, Ambica, et al.
Publicado: (2019)

Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021
por: Ciani, Oriana, et al.
Publicado: (2023)

Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada
por: Lythgoe, Mark P., et al.
Publicado: (2021)

The European Medicines Agency's approval of new medicines for type 2 diabetes
por: Blind, Eberhard, et al.
Publicado: (2018)

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
por: Alsina, Maria, et al.
Publicado: (2019)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
por: Orellana García, Laura Patricia, et al.
Publicado: (2021)

Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
por: Cherla, Avi, et al.
Publicado: (2022)

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
por: Jiang, Di Maria, et al.
Publicado: (2019)

Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study
por: Boyle, Jemma M., et al.
Publicado: (2021)

European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer
por: Stanel, Stefan Cristian, et al.
Publicado: (2017)

Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
por: Schuessler‐Lenz, Martina, et al.
Publicado: (2019)

Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022
por: Ciani, Oriana, et al.
Publicado: (2023)

The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports
por: Erhel, Florian, et al.
Publicado: (2020)

Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications
por: Kwon, Hye-Young, et al.
Publicado: (2018)

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
por: Davis, Courtney, et al.
Publicado: (2017)

A decade comparison of regulatory decision patterns for oncology products to all other non‐oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration
por: Rohr, Ulrich‐P., et al.
Publicado: (2023)

Economic Evaluation of a Geriatric Oncology Clinic
por: Alibhai, Shabbir M. H., et al.
Publicado: (2022)

EHPnet: European Chemicals Agency
por: Dooley, Erin E.
Publicado: (2008)

Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World
por: Fernández-Garza, Luis E., et al.
Publicado: (2023)

Clinically Meaningful Use of Blood Tumor Markers in Oncology
por: Holdenrieder, Stefan, et al.
Publicado: (2016)

Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network
por: Heard, Jean-Michel, et al.
Publicado: (2020)

Socioeconomic disparity trends in diagnostic imaging, treatments, and survival for non‐small cell lung cancer 2007‐2016
por: Shah, Monica, et al.
Publicado: (2020)

Routes of administration, reasons for use, and approved indications of medical cannabis in oncology: a scoping review
por: Vinette, Billy, et al.
Publicado: (2022)

Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
por: Wiedermann, Christian J., et al.
Publicado: (2017)

Financial regulations of the European Space Agency
por: European Space Agency. Paris. Administrative and Finance Committee
Publicado: (1999)

Data processing at the European Space Agency
por: Mazza, C
Publicado: (1982)

Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency
por: Maliepaard, Marc, et al.
Publicado: (2023)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations
por: Yang, Derek Z., et al.
Publicado: (2021)

Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?
por: Teixeira, Tania, et al.
Publicado: (2019)

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form
por: Fudin, Jeffrey, et al.
Publicado: (2016)

2015 Review of Newly Approved Oncologic Therapies
por: Medina, Patrick, et al.
Publicado: (2016)

41st symposium of the European Space Agency
por: Macchetto, F Duccio
Publicado: (2010)

Psychopharmacology at the era of EMEA (European Medicines Agency)
por: Pestana, Luis Camara, et al.
Publicado: (2010)

International Symposium on the History of the European Space Agency
por: Harris, R A
Publicado: (1999)

A bacteriophage journey at the European Medicines Agency
por: Debarbieux, Laurent, et al.
Publicado: (2015)

MEPs approve plans for European CDC
por: Rogers, Arthur
Publicado: (2004)

Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments
por: Winstone, Julie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rls6maogl5l8l7jsqcvnhttu7a